c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia

Abstract

Tyrosine-kinase inhibitor (TKI) therapy for human cancers is not curative, and relapse occurs owing to the continued presence of tumor cells, referred to as minimal residual disease (MRD). The survival of MRD stem or progenitor cells in the absence of oncogenic kinase signaling, a phenomenon referred to as intrinsic resistance, depends on diverse growth… (More)
DOI: 10.1038/nm.4310

6 Figures and Tables

Topics

  • Blog articles referencing this paper

  • Presentations referencing similar topics